首页 | 本学科首页   官方微博 | 高级检索  
     

重组人血管内皮抑制素联合博来霉素治疗恶性胸腔积液的临床研究
引用本文:,刘觉仕,龙林,等. 重组人血管内皮抑制素联合博来霉素治疗恶性胸腔积液的临床研究[J]. 肿瘤药学, 2011, 0(6): 541-543
作者姓名:,刘觉仕,龙林,等
作者单位:湖南省人民医院微创介入医学中心,湖南长沙410005
摘    要:目的观察重组人血管内皮抑制素联合博来霉素治疗恶性胸腔积液的近期疗效及安全性。方法 30例恶性胸腔积液患者随机分为2组,试验组应用重组人血管内皮抑制素联合博来霉素胸腔内灌注,对照组应用博来霉素胸腔内灌注,评估2组近期疗效、KPS评分和不良反应。结果试验组和对照组的有效率分别是86.7%和66.7%(P〈0.05),生活质量改善率分别是80.0%和53.3%(P〈0.05),未出现严重不良反应。结论重组人血管内皮抑制素联合博来霉素是治疗恶性胸腔积液的一种安全、有效的方法。

关 键 词:重组人血管内皮抑制素  博来霉素  恶性胸腔积液

Clinical Research on Recombinant Human Endostatin Combined with Bleomycin in the Treatment of Malignant Pleural Effusion
--. Clinical Research on Recombinant Human Endostatin Combined with Bleomycin in the Treatment of Malignant Pleural Effusion[J]. Anti-Tumor Pharmacy, 2011, 0(6): 541-543
Authors:--
Affiliation:(Minimally Invasive Interventional Medical Center in Hunan Province People's Hospital,Changsha,Hunan,410005)
Abstract:Objective To observe the short-term curative effect and the safety assessment of treatment of malignant pleural effusion with recombinant human endostatin with bleomycin.Method 30 cases of patients with malignant pleural effusionwere divided into 2 groups randomly.The observation group were treated with pleural infusion of recombinant human endostatin combined with bleomycin and the control group were infused with bleomycin only.We evaluate the short-term curative effect,side effects and life quality of the 2 groups.Results The effective rate of the observation group and the control group were 86.7% and 66.7%(P0.050),the rate of improvement of quality of life were 80.0% and 53.3%(P0.050),and no severe side effects happened.Conclusion Recombinant human endostatin combined with bleomycin is safe and effective in the treatment of malignant pleural effusion.
Keywords:Recombinant Human Endostatin  Bleomycin  Malignant Pleural Effusion
本文献已被 维普 等数据库收录!
点击此处可从《肿瘤药学》浏览原始摘要信息
点击此处可从《肿瘤药学》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号